First Patient Dosed In Ph 1/2 Study Of FPI-1966 In Patients With Advanced Solid Tumors Expressing FGFR3 September 7, 2022
Enrollment initiated in Ph 2 Trial of Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma September 7, 2022
FAILED TRIAL: Ph 2 SELECT trial of vopratelimab + pimivalimab combination vs pimivalimab alone did not meet its primary endpoint of mean tumor change in in TISvopra Biomarker-Selected 2L NSCLC Patients September 7, 2022
Ph 3 CodeBreaK 200 trial of LUMAKRAS® (sotorasib) met its primary endpoint of PFS improvement over SoC chemotherapy in KRAS G12C-Mutated NSCLC September 7, 2022
IND Application submitted to the FDA for Ph 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations September 7, 2022
FDA Approves Pemazyre® (Pemigatinib) For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement September 7, 2022
Imfinzi plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced BTC September 7, 2022
